Kohjin Bio Co., Ltd. (TYO:177A)

Japan flag Japan · Delayed Price · Currency is JPY
1,016.00
+15.00 (1.50%)
Jun 3, 2026, 3:30 PM JST
Market Cap5.19B -40.0%
Revenue (ttm)4.94B -5.1%
Net Income251.00M -68.4%
EPS49.10 -68.8%
Shares Out 5.11M
PE Ratio20.69
Forward PEn/a
Dividend25.00 (2.50%)
Ex-Dividend DateMar 30, 2026
Volume7,800
Open999.00
Previous Close1,001.00
Day's Range999.00 - 1,043.00
52-Week Range961.00 - 2,020.00
Beta0.08
Analystsn/a
Price Targetn/a
Earnings DateMay 15, 2026

About Kohjin Bio

Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreserva... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1981
Employees 167
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 177A
Full Company Profile

Financial Performance

In fiscal year 2026, Kohjin Bio's revenue was 4.94 billion, a decrease of -5.13% compared to the previous year's 5.21 billion. Earnings were 251.00 million, a decrease of -68.39%.

Financial Statements